Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2009 May 20;27(15):2530-5.
doi: 10.1200/JCO.2008.20.1061. Epub 2009 Apr 6.

Phase III trial of irinotecan/cisplatin compared with etoposide/cisplatin in extensive-stage small-cell lung cancer: clinical and pharmacogenomic results from SWOG S0124

Primo N Lara Jr  1 , Ronald Natale, John Crowley, Heinz Josef Lenz, Mary W Redman, Jane E Carleton, James Jett, Corey J Langer, J Philip Kuebler, Shaker R Dakhil, Kari Chansky, David R Gandara
Affiliations
Clinical Trial

Phase III trial of irinotecan/cisplatin compared with etoposide/cisplatin in extensive-stage small-cell lung cancer: clinical and pharmacogenomic results from SWOG S0124

Primo N Lara Jr et al. J Clin Oncol. .

Abstract

Purpose: Irinotecan plus cisplatin (IP) improved survival over etoposide plus cisplatin (EP) in Japanese patients with extensive-stage small-cell lung cancer (E-SCLC). To confirm those results and discern the potential role of population-related pharmacogenomics (PG) in outcomes, we conducted a large randomized trial of identical design to the Japanese trial in North American patients with E-SCLC.

Patients and methods: Patients were randomly assigned to IP (irinotecan 60 mg/m(2) on days 1, 8, and 15; cisplatin 60 mg/m(2) day 1, every 4 weeks) or EP (etoposide 100 mg/m(2) on days 1 through 3; cisplatin 80 mg/m(2) day 1, every 3 weeks). Blood specimens for genomic DNA analysis were collected before random assignment in 169 patients.

Results: Of 671 patients, 651 were eligible (324 and 327 patients in the IP and EP arms, respectively). Response rates with IP and EP were 60% and 57%, respectively (P = .56). Median progression-free survival for IP and EP was 5.8 and 5.2 months, respectively (P = .07). Median overall survival for IP and EP was 9.9 and 9.1 months, respectively (P = .71). Severe diarrhea was more common with IP (19% v 3%); severe neutropenia and thrombocytopenia were higher with EP versus IP (68% v 33% and 15% v 4%, respectively). PG analysis showed that ABCB1 (C3435T)T/T (membrane transport) was associated with IP-related diarrhea; UGT1A1 (G-3156A)A/A (drug metabolism) was associated with IP-related neutropenia.

Conclusion: This large North American trial failed to confirm the previously reported survival benefit observed with IP in Japanese patients. Both regimens produced comparable efficacy, with less hematologic and greater gastrointestinal toxicity with IP. These results emphasize the potential importance of PG in interpreting trials of cancer therapy.

PubMed Disclaimer

Conflict of interest statement

Authors' disclosures of potential conflicts of interest and author contributions are found at the end of this article.

Figures

Fig 1.
Fig 1.
Patient disposition (as per CONSORT). CDDP, cisplatin; ITT, intent to treat.
Fig 2.
Fig 2.
Kaplan and Meier progression-free survival curves. CDDP, cisplatin; CPT-11, irinotecan; VP-16, etoposide.
Fig 3.
Fig 3.
Kaplan and Meier overall survival curves. CDDP, cisplatin; CPT-11, irinotecan; VP-16, etoposide.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Jemal A, Siegel R, Ward E, et al. Cancer statistics 2008. CA Cancer J Clin. 2008;58:71–96. - PubMed
    1. Govindan R, Page N, Morgensztern N, et al. Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: Analysis of the Surveillance, Epidemiologic, and End Results database. J Clin Oncol. 2006;24:4539–4544. - PubMed
    1. Clark R, Ihde DC. Small cell lung cancer: Treatment progress and prospects. Oncology (Williston Park) 1998;12:647–658. - PubMed
    1. Albain KS, Crowley JJ, LeBlanc M, et al. Determinants of improved outcome in small cell lung cancer: An analysis of the 2,580 patient Southwest Oncology Group database. J Clin Oncol. 1990;8:1563–1574. - PubMed
    1. Schiller JH, Adak S, Cella D, et al. Topotecan versus observation after cisplatin plus etoposide in extensive stage small cell lung cancer: E7593—A phase III trial of the Eastern Cooperative Oncology Group. J Clin Oncol. 2001;19:2114–2122. - PubMed

Publication types

MeSH terms

Grants and funding